Drugs Monitor, Page 22

(13 Oct 2020) Sarilumab- beneficial clinical outcome and good safety

October 17, 2020

Sarilumab use in severe SARS-CoV-2 pneumonia https://doi.org/10.1016/j.eclinm.2020.100553 Of the 53 SARS-CoV-2(pos) patients receiving Sarilumab, 39(73.6%) were treated in medical wards [66.7% with a single infusion; median PaO2/FiO2:146(IQR:120-212)] while 14(26.4%) in ICU [92.6% with a second infusion; median PaO2/FiO2: 112(IQR:100-141.5)].Within the… Continue reading "(13 Oct 2020) Sarilumab- beneficial clinical outcome and good safety"

(11 Oct 2020) Corticosteroids & Tocilizumab- combination showed beneficial effect in preventing in-hospital mortality

October 14, 2020

Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness https://doi.org/10.1016/j.ijid.2020.09.1486 From March 17 to April 7, 2020, a real-world observational retrospective analysis of consecutive hospitalized adult patients receiving TCZ to treat severe COVID-19… Continue reading "(11 Oct 2020) Corticosteroids & Tocilizumab- combination showed beneficial effect in preventing in-hospital mortality"

(11Oct 2020) Tocilizumab- Improved outcomes and effective in critical and severe patients

October 14, 2020

Efficacy and safety of tocilizumab in COVID-19 patients https://doi.org/10.18632/aging.103988 In this retrospective study, the efficacy and safety of tocilizumab in patients with critical or severe coronavirus disease 2019 (COVID-19) was assessed. 181 patients admitted to Huoshenshan Hospital (Wuhan, China) with… Continue reading "(11Oct 2020) Tocilizumab- Improved outcomes and effective in critical and severe patients"

(11 Oct 2020) Enoxaprin- associated with lower rates of thrombosis and mortality

October 12, 2020

Enoxaparin is associated with lower rates of thrombosis, kidney injury, and mortality than Unfractionated Heparin in hospitalized COVID patients https://www.medrxiv.org/content/10.1101/2020.10.06.20208025v1 While retrospectively analyzing the complete electronic health records (EHRs) of 671 hospitalized COVID-19 patients administered either enoxaparin or unfractionated heparin,… Continue reading "(11 Oct 2020) Enoxaprin- associated with lower rates of thrombosis and mortality"

(08 Oct 2020) Hydroxychloroquine, Ivermectin and Azithromycin- no beneficial effects of individual drugs or their combinations

October 9, 2020

Real-World Effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: Results of a target trial emulation using observational data from a nationwide Healthcare System in Peru https://www.medrxiv.org/content/10.1101/2020.10.06.20208066v2 Among 5683 patients, 200 received HCT, 203 IVM, 1600 AZIT, 692 HCQ… Continue reading "(08 Oct 2020) Hydroxychloroquine, Ivermectin and Azithromycin- no beneficial effects of individual drugs or their combinations"

(08 Oct 2020) Dexamethasone- effective in improving the P/F ratio in COVID-19 patients

October 9, 2020

Comparison of efficacy of Dexamethasone and Methylprednisolone in improving P/F ratio among COVID-19 patients https://www.medrxiv.org/content/10.1101/2020.10.06.20171579v1 The efficacy of methylprednisolone and dexamethasone in reducing inflammation and improving the partial pressure of arterial oxygen and fraction of inspired oxygen (PaO2/FiO2 or P/F)… Continue reading "(08 Oct 2020) Dexamethasone- effective in improving the P/F ratio in COVID-19 patients"

(04 Oct 2020) Corticosteroids- significantly reduced mortality in severe COVID patients

October 5, 2020

Corticosteroid pulses for hospitalized patients with COVID-19. Effects on mortality and in-hospital stay. https://www.medrxiv.org/content/10.1101/2020.09.30.20204719v1 From 2933 patients in a multicenter retrospective cohort study, 257 fulfilled the inclusion and exclusion criteria. 124 patients were on corticosteroid pulses, and 133 were not.… Continue reading "(04 Oct 2020) Corticosteroids- significantly reduced mortality in severe COVID patients"

(01 Oct 2020) Hydroxychloroquine- no clinical benefit of HCQ administered as pre-exposure prophylaxis in hospital-based HCWs

October 5, 2020

Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial https://doi.org/10.1001/jamainternmed.2020.6319 This randomized, double-blind, placebo-controlled clinical trial (NCT04329923) was conducted at 2 tertiary urban hospitals, with enrollment from April 9, 2020,… Continue reading "(01 Oct 2020) Hydroxychloroquine- no clinical benefit of HCQ administered as pre-exposure prophylaxis in hospital-based HCWs"

(30 Sep 2020) Hydroxychloroquine- associated with lower mortality

October 5, 2020

The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients https://doi.org/10.1007/s11739-020-02505-x This study investigates the association between the treatment with hydroxychloroquine and mortality in patients admitted with COVID-19. Routinely recorded, clinical data, up to the 24th of April… Continue reading "(30 Sep 2020) Hydroxychloroquine- associated with lower mortality"

(30 Sep 2020) Tocilizumab- effective in COVID-19 patients with severe respiratory impairment receiving NIV

October 5, 2020

Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation https://doi.org/10.1186/s13054-020-03306-6 Out of 79 patients, 41 were treated with TCZ. Twenty-eight patients received intravenous (IV) TCZ and 13 patients received subcutaneous (SC) TCZ. In-hospital overall mortality rate was 38%… Continue reading "(30 Sep 2020) Tocilizumab- effective in COVID-19 patients with severe respiratory impairment receiving NIV"